Observational studyInternal medicine (Tokyo, Japan)2017
Clinical Characteristics of Stenotrophomonas maltophilia Bacteremia: A Regional Report and a Review of a Japanese Case Series.
Observational study in Internal medicine (Tokyo, Japan), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 50 citations in OpenAlex.
- Risk Factors Associated with Mortality in Nosocomial Stenotrophomonas maltophilia Pneumonia: A Single-Center Retrospective Study.Mediterranean journal of hematology and infectious diseases · 2026Article
- The Other Face ofAntibiotics (Basel, Switzerland) · 2026Article
- Risk factors for mortality in Stenotrophomonas maltophilia bacteraemia: a 22-year retrospective study in a Japanese acute care hospital.Access microbiology · 2026Article
- Clinical presentation and outcomes of bloodstream infection with intrinsically carbapenem-resistant non-fermenting gram-negative organisms: Stenotrophomonas maltophilia, Elizabethkingia spp. and Chryseobacterium spp. in Singapore, from 2012 to 2024.BMC infectious diseases · 2025Article
- Article
- Antibiotic utilization trends in Veterans Affairs patients withAntimicrobial stewardship & healthcare epidemiology : ASHE · 2024Article
- Review
- Intra-Abdominal Abscess and Bacteremia Due toInfection and drug resistance · 2023Article
- Article
- OvercomingOpen forum infectious diseases · 2022Review
- Article
- Risk Factors for Mortality in Hospitalized Patients withInfection and drug resistance · 2022Article
- Healthcare-Associated Stenotrophomonas maltophilia Bacteraemia: Retrospective Evaluation of Treatment and Outcome.Cureus · 2021Article
- Article
- Emergent Pneumonia in Children.Frontiers in pediatrics · 2021Review
- Stenotrophomonas maltophilia: An Emerging Pathogen of the Respiratory Tract.The American journal of case reports · 2020Article
- Characteristics of Stenotrophomonas maltophilia infection in children in Sichuan, China, from 2010 to 2017.Medicine · 2020Article
- Article
- Risk factors for mortality in patients with Stenotrophomonas maltophilia bacteremia and clinical impact of quinolone-resistant strains.BMC infectious diseases · 2019Article
- Epidemiological Trends and Resistance Associated withDiseases (Basel, Switzerland) · 2019Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective Stenotrophomonas maltophilia is an emerging nosocomial pathogen that causes fatal infections in critically ill or immunocompromised patients. S. maltophilia bacteremia (SMB) is a rare condition, and its clinical characteristics in Japanese settings are not well known. Methods The medical charts of patients with SMB were retrospectively reviewed at two medical facilities (Okayama University Hospital and Tsuyama Chuo Hospital) for seven years. The data were analyzed along with those previously reported from other Japanese facilities. Result A total of 181 patients (110 men and 71 women) were evaluated. The major underlying diseases included hematologic malignancy (36.5%), solid organ malignancy (25.4%), and neutropenia (31.5%). The recent use of carbapenem was seen in 56.9% of the cases in total, and more than one-third of the patients in our hospitals were treated with carbapenem at the onset of SMB. Of 28 (63.6%) of 44 cases treated for S. maltophilia, those who did not survive were more likely to have been treated with broad-spectrum antibiotics. A multivariate analysis revealed that a higher updated Charlson Comorbidity Index [odds ratio (95% confidence interval), 1.75 (1.11-2.75); p=0.015] and intubation [odds ratio (95% confidence interval), 12.6 (1.62-97.9); p=0.016] were associated with mortality in our cases. Pathogens were often resistant to ceftazidime but susceptible to minocycline, trimethoprim/sulfamethoxazole, and fluoroquinolones. The overall mortality rates within 30 and 90 days were 37.5% and 62.5%, respectively. Conclusion The clinical characteristics of SMB in Japanese cases were similar to those reported from other countries. Clinicians should be aware that breakthrough infection by S. maltophilia may occur during administration of carbapenem.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.